Hoechst, Rhone Revise Their Merger Plans
Hoechst and Rhone-Poulenc revised a plan to merge and agreed to complete by November the $22-billion deal that would create the world’s biggest drug maker, bringing forward by two years a process that two months ago looked as if it would collapse. Under a revised deal, Hoechst shareholders will receive three shares of Paris-based Rhone-Poulenc for every four Hoechst shares, giving the German drug maker’s owners 53% of Aventis, the new company. Under the original plan, the German group would have held a 50% share. The new company will be based in Strasbourg, France, while the drug division, Aventis Pharma, will be based in Frankfurt, Germany. The changes to the original two-step, three-year merger model follow opposition from Hoechst’s largest shareholder, Kuwait Petroleum Corp., which was concerned that the plan would damage its investment.
More to Read
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.